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Abstract. The present study shows that chronic administration of the Cannabinoid receptor type 1 (CB1) receptor agonist
arachidonyl-2-chloroethylamide (ACEA) at pre-symptomatic or at early symptomatic stages, at a non-amnesic dose, reduces
the cognitive impairment observed in double APP(swe)/PS1(1dE9) transgenic mice from 6 months of age onwards. ACEA
has no effect on amyloid- (A) production, aggregation, or clearance. However, ACEA reduces the cytotoxic effect of A42
oligomers in primary cultures of cortical neurons, and reverses A-induced dephosphorylation of glycogen synthase kinase-3
(GSK3) in vitro and in vivo. Reduced activity of GSK3 in ACEA-treated mice is further supported by the reduced amount
of phospho-tau (Thr181) in neuritic processes around A plaques. In addition, ACEA-treated mice show decreased astroglial
response in the vicinity of A plaques and decreased expression of the pro-inflammatory cytokine interferon- in astrocytes
when compared with age-matched vehicle-treated transgenic mice. Our present results show a beneficial effect of ACEA at both
the neuronal, mediated at least in part by GSK3 inhibition, and glial levels, resulting in a reduction of reactive astrocytes and
lower expression of interferon-. As a consequence, targeting the CB1 receptor could offer a versatile approach for the treatment
of Alzheimer’s disease.
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INTRODUCTION
Alzheimer’s disease (AD) is a devastating neu-
rodegenerative disorder affecting one in eight people
aged 65 and older in Western countries [1]. The lim-
ited effectiveness of current therapies against AD
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highlights the need for intensified research efforts
devoted to developing new agents for preventing or
retarding the disease process. In recent years, interest
has increasingly focused on the potential neuropro-
tective properties of cannabinoids in AD [2]. The
endocannabinoid system is composed of at least two
well-characterized cannabinoid Gi/o-coupled recep-
tors, CB1 and CB2, their endogenous ligands, and the
enzymes related to their synthesis and degradation [3].
The CB1 receptor is widely expressed within the cen-
tral nervous system [4], in both neurons and glial cells
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[3, 5], where it regulates important brain functions
[6, 7]. Moreover, CB1 receptor plays a role in pro-
tection against neurotoxicity [8] and in the induction
of repair mechanisms in response to neuronal dam-
age [9]. In contrast, CB2 receptor is mainly expressed
in the immune system, including microglia [10]. The
activation of CB2 receptor reduces the microglial pro-
duction of pro-inflammatory molecules [11], which
is also implicated in the control of neural survival
[12]. Thus, the attention paid to cannabinoids in AD
is mainly due to their ability to reduce neuroin-
flammation through the activation of CB1 and CB2
receptors [13–16], but also through reducing the harm-
ful action of amyloid- peptide (A) and promoting
the brain’s intrinsic repair mechanisms [17]. Among
the neuroinflammation-independent mechanisms asso-
ciated with cannabinoid-induced neuroprotection
against A, the CB1 receptor plays a remarkable
role. In this line, recent studies have reported that the
activation of CB1 receptor preserves neuron viability
by reducing A-induced lysosomal membrane per-
meabilization [18] and by suppressing pro-apoptotic
signaling pathways [19]. The diversity of mechanisms
involved in the neuroprotective role of CB1 receptor in
AD suggests that targeting this receptor could repre-
sent a versatile approach toward the treatment of AD.
Based on this premise, the present study is specifically
focused on the potential properties of a CB1 recep-
tor agonist in an animal model of AD. We selected
the synthetic agonist arachidonyl-2-chloroethylamide
(ACEA) because of its high affinity and specificity to
the CB1 receptor [20].
Double APP(swe)/PS1(1dE9) (APP/PS1) mice
are used in the present study as a model of famil-
ial AD because they reproduce some of the most
relevant features of the disease, including cognitive
impairment and several pathological alterations such
as A plaques, dystrophic neurites around A depo-
sition, and synaptic abnormalities from the age of
six months onwards [21, 22]. APP/PS1 mice do
not replicate neurofibrillary tangles observed in AD
brains, but do exhibit hyperphosphorylated tau pro-
tein in the vicinity of A plaques, as also observed
in APP Tg2576 mice [23]. Therefore, we consider
that APP/PS1 mice represent valuable tools for
the evaluation of novel therapeutic strategies against
AD.
In the present study, we provide data reveal-
ing a reduction in the cognitive impairment of
APP/PS1 mice treated during pre-symptomatic and
early symptomatic stages with a non-amnesic dose of
a CB1 receptor agonist, supporting the hypothesis that
cannabinoid compounds may have potential use in the
treatment of AD.
MATERIALS AND METHODS
Primary cultures of cortical neurons
Cortical cells were isolated from 18-day-old OF1
mouse embryos. The procedure was approved by
the Ethics Committee of the Institut Municipal
d’Investigacions Me`diques-Universitat Pompeu Fabra.
Cortex were aseptically dissected and tripsinized. Cells
were seeded in phenol-red-free Dulbecco’s Modified
Eagle Medium (DMEM) plus 10% horse serum on
to 1% poly-L-Lysine coated plates. After 120 min,
medium was removed and neurobasal medium (high-
glucose phenol-red-free DMEM; Gibco BRL) was
added containing 1% B27 supplement (Gibco BRL),
plus antibiotics. On day 3 of culture, cells were treated
with 2M 1--D-arabinofuranosylcytosine (Sigma)
for 24 h to eliminate proliferating non-neuronal cells.
Cultured cortical cells were used for the experiments
on day 10.
Cannabinoid protection assays in cortical neurons
Primary cultures of mouse cortical neurons
(7.5 × 104 cells/300L/well) were assayed in neu-
robasal supplemented with B27 without antioxi-
dants in 24 well culture-plates. Cells were treated
with 0.1 or 1M ACEA, and then PBS (con-
trol) or 1M A oligomers were added to
wells. Cells were incubated for 24 h. Cell viabil-
ity was measured by 3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reduction.
Briefly, 33L of MTT stock solution (5 mg/mL) was
added and after 2 h the reaction was stopped with
300L of DMSO. MTT reduction was determined in
a plate reader spectrophotometer at 540 and 650 nm.
Control cells were taken as 100%.
Animals
The experiments were carried out on male
APP/PS1 mice and wild-type littermates aged 3, 6,
or 12 months at the beginning of the study. The gen-
eration of mice expressing the human mutated forms
APPswe and PS1dE9 (APP/PS1) has been already
described [21]. In the present work, identification of
transgenic mice was carried out as follows: genomic
DNA was isolated from 1-cm tail clips and genotyped
by polymerase chain reaction (PCR) technique using
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the PCR conditions proposed by Jackson Laboratory.
Animals were maintained under standard animal hous-
ing conditions in a normal 12-h dark-light cycle with
free access to food and water. The sample size for
experimentation was computed using the Power and
Precision software (Biostat, Englewood, NJ, USA),
assuming a power of 95% and no missing data. Ani-
mal procedures were conducted according to ethical
guidelines (European Community Council Directive
86/609/EEC) and approved by the local ethical com-
mittee (UB-IDIBELL).
Drugs and pharmacological treatment
The selective CB1 receptor agonist ACEA was sup-
plied by Tocris Bioscience® (Bristol, UK). ACEA
(1.5 mg/kg) was dissolved in 5% ethanol, 5% Tween,
and 90% saline, and this mixture was injected intraperi-
toneally (i.p.) in a volume of 10 mL/kg body weight.
Animals treated during the pre-symptomatic phase
received one daily administration for 5 weeks with
ACEA (wild-type, n = 10; APP/PS1, n = 8) or the
corresponding vehicle (wild-type, n = 9; APP/PS1,
n = 7) starting at 3 months of age. The behavioral test-
ing was performed when animals were six months
of age. A second group of animals were treated dur-
ing the early symptomatic phase. These mice aged
6 months were treated once daily for 5 weeks with
ACEA (wild-type, n = 10; APP/PS1, n = 9) or the
corresponding vehicle (wild-type, n = 6; APP/PS1,
n = 7). After 10 days of washing period, animals
were subjected to behavioral evaluation. A third group
of 6-month-old mice (n = 5) was used for the acute
experiment to evaluate the GSK3 levels. Animals
were administered ACEA (1.5 mg/kg) and sacrificed
30 min later. Their brains were dissected on ice,
immediately frozen, and stored at −80◦C until pro-
cessing.
Behavioral evaluation of cognitive performance
Two-object recognition test
This paradigm was performed in a V-maze (Panlab,
Barcelona, Spain) because it improves the exploration
time of the animals with respect to a classical open
field. On day 1, mice were habituated for 9 min,
allowing them to freely explore the apparatus. On the
second day, mice were placed for 9 min in the maze,
where two identical objects were situated at the end
of the arms, and the time that the mice spent explor-
ing each object was recorded. Then, 24 h after the
training session, animals were placed again in the
V-maze where one of the two familiar objects was
replaced by a novel object. The time that the animals
spent exploring the two objects was recorded and an
object recognition index was calculated as the differ-
ence between the time spent exploring the novel and
the familiar object, divided by the total time spent
exploring the two objects. Animals exhibiting mem-
ory impairments revealed a lower object recognition
index [24].
Active avoidance test
After the two-object recognition test, the animals
were allowed to rest for 4 days before starting the
active avoidance test. Then, the mice were trained to
avoid an aversive stimulus associated with the presen-
tation of a conditioned stimulus (CS) in a two-way
shuttle box apparatus (Panlab, Barcelona, Spain). The
CS was a light (10 W) switched on in the compart-
ment in which the mouse was placed. The CS was
received 5 s before the onset of the unconditioned stim-
ulus (US) and overlapped it for 25 s. At the end of
the 30-s period, both CS and US were automatically
turned off. The US was an electric shock (0.2 mA)
continuously applied to the grid of the floor. A condi-
tioned response was recorded when the animal avoided
the US by changing from the compartment where it
received the CS to the opposite compartment within the
5 s period after the onset of the CS. If animals failed
to avoid the shock, they could escape it by crossing
during the US (25 s) and this was recorded as uncon-
ditioned response. Between each trial session, there
was an inter-trial interval of 30 s. Animals were sub-
jected to five daily 100-trial active avoidance sessions.
Each day, the mice were placed in the shuttle box
for 10 min before the start of each session to allow
them to explore the box. Data are expressed as the
total number of conditioned changes, converted to the
area under the curve (AUC) using a standard trapezoid
method.
Tissue collection
At the end of the behavioral testing, the animals
were sacrificed and their brains were removed. One
brain hemisphere was dissected on ice, immediately
frozen and stored at −80◦C until processing for the
A soluble quantification. The other brain hemisphere
was fixed in 4% paraformaldehyde and processed for
immunohistochemistry.
442 E. Aso et al. / ACEA Protection in AβPP/PS1 Mice
Aβ immunohistochemistry
Tissue samples were embedded in paraffin and
coronal sections (4m) were cut with a microtome.
De-waxed sections were incubated with 98% formic
acid (3 min) and then treated with citrate buffer
(20 min) to enhance antigenicity. Then, the endoge-
nous peroxidases were blocked by incubation in 10%
methanol-1% H2O2 solution (15 min). Sections were
blocked with 3% normal horse serum solution and
then incubated at 4◦C overnight with the primary
antibodies against A (1 : 50, Dako, Clone 6F/3D).
Sections were subsequently rinsed and incubated with
biotinylated secondary antibody (Dako), followed by
EnVision + system peroxidase (Dako) and finally with
the chromogen diaminobenzidine and H2O2. Some
sections were incubated without the primary antibody.
No immunostaining was detected in these sections.
Sections were lightly counterstained with haema-
toxylin. After staining, the sections were dehydrated
and cover-slipped for microscopic observation. The
A burden in neocortex was calculated as the per-
centage of the A deposition area with respect to the
total area in 9 representative pictures, corresponding
to the main regions where A deposition is observed
in APP/PS1 mice (Fig. 4A). One section of the hip-
pocampus was used for similar quantification of the
A burden. Sections from all the APP/PS1 animals
were evaluated by using the Analysis tool of the soft-
ware Adobe® Photoshop® CS4. This Analysis tool
allows selection by color range and quantification
of the specific immunostaining density of each pic-
ture.
Aβ soluble quantiﬁcation: Enzyme-linked
immunosorbent assay (ELISA)
Fresh-frozen mouse brain cortexes were homog-
enized in 4 volumes (wt:vol) of TBS extraction
buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris (pH
7.4), 5 mM EDTA and protease inhibitor cocktail
(Roche)). Homogenate was spun 100,000 g × 1 h, and
the supernatant saved as the soluble fraction for A
quantifications. The A40 and A42 Human ELISA
kits (Invitrogen™ Corporation, Camarillo, CA, USA)
were used to quantify the levels of A40 and A42
proteins in the brain soluble fractions, respectively. The
quantitative determination was carried out according to
the manufacturer’s instructions. A40 and A42 levels
were normalized to the total amount of protein from
each individual sample. A ratio was calculated of the
A42 levels with respect to those of A40.
Aβ aggregation
The A42 (Sigma) stock solution was prepared by
dissolving the peptide in DMSO to a final concentra-
tion of 15g/L. The turbidometric assay was carried
out at room temperature, within a dark chamber in a
96-well plate under continuous shaking (300 rpm).
Each well contained 100 ng/L A42 dissolved in
100L PBS pH 5.5 and 0.1 or 1M ACEA.
Absorbance at 405 nm was followed over time.
Double-labeling immunoﬂuorescence
CB1 and Aβ or GFAP double-immunoﬂuorescence
For CB1 and A or GFAP double-immunostaining,
free-floating sections were incubated with 98% formic
acid (3 min) to enhance antigenicity and then thor-
oughly washed in PBS. Tissue permeabilization was
facilitated by incubation with 0.25% TX-100 together
with 10% normal goat serum for non-specific bind-
ing blocking for 90 min at room temperature. Sections
were then incubated with the combination of primary
antibodies against CB1 (1 : 500, Frontier Science Co.
Ltd, Japan) and A (1 : 50, Boehringer-Mannheim) or
GFAP (1 : 250, Dako) overnight at 4◦C. After wash-
ing, the sections were incubated for 60 min with
Alexa488 or Alexa546 (1 : 400, Molecular Probes)
fluorescence secondary antibodies against the cor-
responding host species and subsequently washed
in PBS. Then, nuclei were stained with DRAQ5™
(1 : 2000, Biostatus Ltd, Leicestershire, UK), thor-
oughly washed, mounted onto polylysine-coated slides
in Immuno-Fluore Mounting medium (ICN Biomed-
icals), sealed, and dried overnight. Sections were
examined with a Leica TCS-SL confocal micro-
scope.
Densitometric quantiﬁcation of CB1
The presence of dystrophic neurites in the vicinity of
the A plaques is supposed to indicate that the integrity
of the neurons is compromised in the areas directly
influenced by A deposition in APP/PS1 mice [22].
In contrast, the functionality of the neurons far from
A plaques should be more preserved since there is
no evidence of dystrophic neurites in such areas. Thus,
in order to estimate the influence of A deposition
in the CB1 receptor cortical density, the CB1 protein
expression levels were evaluated in an area free from
the A plaque as well as in the vicinity of A depo-
sition. The percentage of the CB1 staining area was
calculated (a) with respect to the total cortex (wild-
type mice) or to a 225m × 225m area in the case
E. Aso et al. / ACEA Protection in AβPP/PS1 Mice 443
of an area free from A deposition (APP/PS1) and
(b) with respect to an area equivalent to 4 times the
A plaque (arbitrary reference based on the dystrophic
neurites and presence of reactive gliosis and taken in
order to normalize the A extension), both in 5 rep-
resentative pictures taken from the neocortex of each
animal (n = 5 per group) using the software Adobe®
Photoshop® CS4.
Glial, tau phosphorylation and Aβ or Interferon-γ
(IFN-γ) double-immunoﬂuorescence
In the case of the glial, tau phosphorylation and
A or IFN- double immunostaining, de-waxed sec-
tions were stained with a saturated solution of Sudan
black B (Merck) for 30 min to block the autofluores-
cence of lipofuscin granules present in cell bodies,
then rinsed in 70% ethanol and washed in distilled
water. The sections were treated with 98% formic acid
(3 min, in the case of A immunostaining) and with
citrate buffer to enhance antigenicity, and then incu-
bated at 4◦C overnight with combinations of primary
antibodies against A (1 : 50, Dako), IFN- (1 : 50,
Millipore) and tau-P(Thr181) (1 : 250, Calbiochem),
GFAP (1 : 250, Dako) or Iba1 (1 : 250, Wako). After
washing, the sections were incubated with Alexa488
or Alexa546 (1 : 400, Molecular Probes) fluorescence
secondary antibodies against the corresponding host
species. After washing, the sections were mounted
in Immuno-Fluore Mounting medium (ICN Biomedi-
cals, Solon, OH, USA), sealed, and dried overnight.
Sections were examined with an Olympus BX51
microscope.
Densitometric quantiﬁcation of glia and tau
phosphorylation around Aβ plaques
Astrocytic and microglial responses to A deposi-
tion, as well as tau phosphorylation, were evaluated
by densitometric quantification of GFAP and Iba1 or
tau-P(Thr181) protein expression levels around A
plaques, respectively. The GFAP, Iba1, and tau phos-
phorylation immunostaining was in reference to the
A plaque area in 5 representative pictures taken from
the neocortex of each animal (n = 5 per group) using
the software Adobe® Photoshop® CS4.
Densitometric quantiﬁcation of IFN-γ expression
in astrocytes
IFN- immunostaining colocalized with GFAP, but
not Iba1, immunostaining. Thus, the expression levels
of IFN-g were evaluated by densitometric quantifica-
tion and in reference to the GFAP immunostained area
in 5 representative pictures taken from the neocortex
of each animal (n = 5 per group) using the software
Adobe® Photoshop® CS4.
P-Ser9-glycogen synthase kinase-3β (GSK3β)
immunolabeling assay
Primary cultures of mouse cortical neurons
(7.5 × 104 cells/300L/well) were seeded on to
poly-L-coated coverslips and assayed in Neurobasal
supplemented with B27 without antioxidants in
24-well culture plates. Cells were incubated for
30 min with 1M ACEA and PBS (control) or
1M A oligomers. Cells were incubated for 24 h.
Then, neurons were fixed with 4% paraformalde-
hyde and permeabilized with 0.1% Triton X-100.
Immunostaining was done with polyclonal rabbit
anti-p-Ser9-GSK3 antibody (1 : 200; Calbiochem)
or monoclonal rabbit anti-tubulin (1 : 1000; Sigma).
Secondary antibodies were Alexa Fluor 488 goat anti-
rabbit (1 : 700; Molecular Probes) and Alexa Fluor 555
goat anti-rabbit (1 : 1000; Molecular Probes). Cover-
slips were mounted and analysed under a confocal
microscope.
P-Ser9-GSK3β quantiﬁcation
Cortical neurons
Primary cultures of mouse cortical neurons (106
cells/2 mL/well) were assayed in Neurobasal sup-
plemented with B27 without antioxidants in 6-well
culture plates. Cells were pre-incubated for 15 min
with 0.5M Rimonabant (a specific CB1 inhibitor).
Then, ACEA 1M and PBS (control) or 1M A
oligomers were added to wells. Cells were incubated
for 30 min and lysed (137 mM NaCl; 20 mM Tris-
HCl, pH 8.0; 1% NP-40; 10% glycerol; 1 mM sodium
vanadate; 5 mM sodium pyrophosphate; 100 mM NaF;
40 mM glycerol phosphate; 1 mM PMSF; 0.15M
aprotinine; 11M leupeptine; 1.5M pepstatine).
Wild-type and AβPP/PS1 mice
Wild-type and APP/PS1 mice were acutely treated
with vehicle or ACEA as indicated in section 2.4.
Frozen brain areas were dounze-homogenized in the
same lysis buffer described above. Samples were
homogenized in 30l lysis buffer/mg wet weight.
Immunoblot analysis
After 20 min of incubation with lysis buffer in
agitation at 4◦C, both cell and brain samples were cen-
trifuged for 30 min at 16,000 g, and the supernatant
was recovered and stored at −80◦C. Protein content
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was determined using the DC Protein Assay (Bio-Rad)
following the manufacturer’s instructions.
GSK3 and phospho-Ser9 GSK3 levels were
quantified by western blotting. Equal amounts of
lysates (20g per lane) were separated by SDS-PAGE
(8%) before electrophoretic transfer on to nitrocellu-
lose membrane (Bio-Rad, Spain). Membranes were
blocked for 1 h at room temperature in Tris-buffered
saline (100 mM NaCl, 10 mM Tris, pH7.4) with 0.1%
Tween 20 (TTBS) and 5% nonfat milk. Afterwards,
membranes were incubated overnight with the mono-
clonal rabbit anti-phospho-Ser9 anti-GSK3 (1 : 1000;
Cell Signaling Technology) in TTBS with 5% non-
fat milk, and polyclonal rabbit anti-GSK3 (1 : 1000,
Chemicon) in TTBS with 5% bovine serum albumin.
The secondary antibody was a horseradish peroxidase-
conjugated anti-rabbit (1 : 10000; Sigma). Samples
were incubated 1 h at room temperature. Bands were
visualized by enhanced chemiluminescence detec-
tion (ECL AdvanceTM, Amersham Biosciences). The
value of active phospho-Ser9 GSK3 was normalized
to the amount of total GSK3 in the same sample and
expressed as a percentage of control treatment.
Statistical analyses
Data were analyzed by two-way ANOVA with geno-
type and treatment or age as between factors, followed
by Tukey’s post hoc test when required. Learning data
(conditioned changes) were analyzed by three-way
ANOVA with day (repeated measures), genotype and
treatment as between factors. A, glia, tau, and IFN-
quantifications were analyzed by Student’s t-test. The
in vitro experiment data were evaluated statistically
using one-way ANOVA followed by Tukey’s post hoc
test. In all the experiments, the significance level was
set at p < 0.05.
RESULTS
ACEA protection against Aβ-induced neurotoxicity
As a preliminary approach to the study of the poten-
tial cannabinoid protection in APP/PS1 mice, we
tested whether the CB1 receptor agonist ACEA could
induce a protective effect against A-induced neuro-
toxicity in vitro. In the present study, we observed that
ACEA protected cortical neurons against A oligomer
insult (Fig. 1). One-way ANOVA revealed significant
effect of A oligomer in cell viability (F(3,14) = 12.97,
p < 0.001). Tukey’s post hoc test indicated that the
exposure to A oligomer produced a reduction in the
Fig. 1. Neuroprotection by ACEA against A oligomer neurotoxi-
city in primary cultures of cortical neurons. Cell viability of cortical
neurons exposed to A42 oligomers in the absence or presence
of ACEA. Data are the mean ± SEM of 3–6 independent experi-
ments. p < 0.05, p < 0.001 compared to control. p < 0.05,
p < 0.01 compared to A (one-way ANOVA followed by Tukey’s
post hoc analysis).
cell viability (p < 0.001), which was also significant in
the presence of 0.1M ACEA (p < 0.05), compared to
control cells. Interestingly, a significant increase in via-
bility was observed in cells exposed to A oligomer
in the presence of the 0.1 (p < 0.05) or 1M ACEA
(p < 0.01) when compared to A-treated cells.
Progressive age-dependent loss of CB1 receptor in
the neocortex of AβPP/PS1 mice
In an attempt to assess the relevance of CB1
receptor in AD, we evaluated the expression lev-
els of this receptor in the neocortex of APP/PS1
mice, an animal model of familial AD [21], at dif-
ferent stages of the neurodegenerative progression
by immunofluorescence techniques and quantitative
densitometry. Our results revealed a progressive age-
dependent reduction in the levels of CB1 receptor
in APP/PS1 mice from 6 months when compared
to age-matched wild-type littermates (Fig. 2). Two-
way ANOVA indicated a significant effect of age
(F(2,64) = 16.84, p < 0.001) and interaction between
age and genotype (F(2,64) = 6.61, p < 0.001) in the
cortical areas free from A deposition (Fig. 2Y).
Subsequent one-way ANOVA revealed an age effect
in both APP/PS1 (F(2,29) = 15.82, p < 0.001) and
wild-type animals (F(1,32) = 9.41, p < 0.01). Tukey’s
post hoc test showed a significant reduction in CB1
levels in APP/PS1 aged 12 months when com-
pared to 3- and 6-month-old mice (p < 0.001 and
p < 0.01, respectively), in contrast to the increase in
CB1 immunostaining in wild-type littermates at 6
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compared to 3 months of age (p < 0.05). However,
the levels of CB1 were also reduced in wild-type
mice at 12 months when compared to 6 months of
age (p < 0.001). Comparing genotypes, we observed
an increase in the CB1 levels in APP/PS1 aged
3 months (p < 0.05) but reduced CB1 immunostain-
ing at 6 months (p < 0.05) and 12 months (p < 0.01)
when compared to age-matched wild-type litter-
mates.
In the area surrounding the A plaques, a reduc-
tion in the CB1 immunostaining in APP/PS1 animals
aged 12 months was also observed when compared to
6-month-old mice (t(23) = 5.39, p < 0.001) (Fig. 2Z).
The effect of ACEA on the cognitive performance
of AβPP/PS1 mice treated during the
pre-symptomatic phase
We evaluated the effect of a CB1 receptor agonist
in vivo at the cognitive level in our animal model of
AD. APP/PS1 mice chronically treated for 5 weeks
with ACEA during the pre-symptomatic phase did not
show the cognitive impairment exhibited in the two-
object recognition test by vehicle control APP/PS1
mice at the age of 6 months (Fig. 3B left).
Similarly, APP/PS1 mice chronically treated
with ACEA during the pre-symptomatic phase did
not exhibit the learning impairment exhibited by
APP/PS1 mice chronically treated with vehicle in the
active avoidance test at the age of 6 months (Fig. 3C
and 3D left). See Table 1 for statistical details.
ACEA treatment during early stages of the
symptomatic phase partially reversed the cognitive
deﬁcits in AβPP/PS1 mice
The daily stimulation of CB1 receptors for 5 weeks
at the early stages of the symptomatic phase (6
months) reversed the cognitive impairment exhibited
by APP/PS1 mice on the two-object recognition test
(Fig. 3B, right).
In contrast, the CB1 agonist was not able to signif-
icantly reduce the impairment shown by APP/PS1
mice aged 6 months at the beginning of the treatment
in the active avoidance paradigm (Fig. 3C right). See
Table 2 for statistical details.
Cortical and hippocampal Aβ quantiﬁcation
One possible mechanism used by ACEA to protect
APP/PS1 mice would be a direct effect reducing A
production. To address this point, we quantified the
A burden in neocortex and hippocampus (Fig. 4) as
well as the soluble A production and aggregation
(Fig. 5) after ACEA treatment. We found that chronic
treatment with ACEA did not significantly modify the
A burden in the cortex of APP/PS1 mice either
when they were chronically treated during the pre-
symptomatic phase or during the early stages of the
symptomatic phase (Fig. 4B and C). Similarly, the A
burden was not modified in the hippocampus, a region
where A deposition starts later than in the neocor-
tex (Fig. 4D). ACEA did not significantly modify the
A40 or A42 protein levels (Fig. 5A) or the ratio
between them (Fig. 5B) in the soluble cortical frac-
tion of APP/PS1, either when they were chronically
treated during the pre-symptomatic phase or during
the early stages of the symptomatic phase. A possible
direct effect of ACEA on A aggregation due to its
hydrophobic nature was ruled out since A fibrillation
was not affected by the presence of 0.1 or 1M ACEA
(Fig. 5C).
Chronic treatment with ACEA did not modify the
expression of CB1 receptor levels in the neocortex
of AβPP/PS1 mice
In order to evaluate a possible down-regulation of
CB1 receptor after chronic exposure to the specific
agonist ACEA, we analyzed the levels of this receptor
in the neocortex of treated animals by immunofluo-
rescence. Our results indicated that the ACEA dose
used in our study did not significantly modify the lev-
els of CB1 receptor in the neocortex of APP/PS1
mice (Fig. 6). Two-way ANOVA indicated a sig-
nificant effect of genotype (F(1,51) = 8.26, p < 0.01)
but no interaction between genotype and treatment
in the CB1 immunostaining in the cortical areas
free from A deposition (Fig. 6M). Tukey’s post
hoc test revealed a reduction in the CB1 levels in
vehicle-treated APP/PS1 mice (p < 0.05), but not in
ACEA-treated animals, with respect to wild-type lit-
termates.
Reduction of the astrocytic responses associated
with Aβ deposition after ACEA treatment
Hypertrophic astrocytes and reactive microglia
were observed in the vicinity of A plaques in
APP/PS1 mice. Double immunofluorescence tech-
niques revealed that chronic stimulation with the
CB1 agonist ACEA produced a reduction in the
area of astrocytes surrounding the A plaques
when compared to vehicle-treated animals during the
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Fig. 2. Representative images of the double-immunofluorescence for CB1 receptor (red, A, E, I, M, Q, and U) and A (green, B, F, J, N, R,
and V) in coronal sections of wild-type and APP/PS1 mice aged 3 months (A to H), 6 months (I to P), or 12 months (Q to X), indicating an
age-dependent CB1 downregulation in the cortical areas free from amyloid deposition (white-line squares, A, E, I, M, Q, and U. A, E, I, and Q
magnified in D, H, L, and T), as well as in the areas surrounding amyloid plaques (white-line circles, A, E, I, M, Q, and U. M and U magnified
in P and X). C, G, K, O, S, and W: merge. Nuclei are stained in blue. Scale bars represent 75m. Quantification of CB1 labeling in wild-type
and APP/PS1 mice aged 3, 6, or 12 months revealed an age-dependent CB1 downregulation in (Y) the cortical area free from A deposition
as well as in (Z) the area surrounding A plaques. Data are expressed as the mean values ± SEM (n = 5 pictures from each animal, 3 animals
per group). p < 0.05, p < 0.01 compared to wild-type. p < 0.01, p < 0.001 compared to 6 months. §p < 0.05, §§§p < 0.001 compared
to 3 months (two-way ANOVA followed by Tukey’s post hoc analysis).
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Fig. 3. Cognitive improvement of APP/PS1 mice chronically treated with ACEA during the pre-symptomatic phase (left: treatment beginning
at 3 months) or during the beginning of the symptomatic phase (right: treatment beginning at 6 months). A) Acute administration of ACEA at
the dose utilized in the present study (1.5 mg/kg, i.p.) does not produce amnesia-like effects in wild-type mice when evaluated in the two-object
recognition test. B) Memory performance in the V-maze at 6 months of age (left) or at 8 months of age (right). APP/PS1 mice chronically treated
with vehicle exhibited a significant reduction in the recognition index when compared to corresponding wild-type littermates. Chronic ACEA
administration completely reversed the APP/PS1 memory deficiency when compared to vehicle-treated animals in both pre-symptomatic (left)
and symptomatic (right) groups of animals. C) Active avoidance test shows a decrease in the learning performance in vehicle-treated APP/PS1
mice when compared with age-matched wild littermates. This learning impairment was not evidenced after ACEA chronic administration in
animals treated during the pre-symptomatic phase (left), in contrast to the symptomatic group (right). D) Statistical analysis from the Area
Under the Curve (AUC) representing the data from the active avoidance test revealed a significant reduction in the learning performance of
APP/PS1 mice treated with vehicle during the pre-symptomatic phase, but an improvement in ACEA-treated animals (left). However, this
improvement was not observed in animals treated with ACEA at the early symptomatic phase. Data are expressed as the mean values ± SEM
(n = 6–10 per group). p < 0.05, p < 0.01, p < 0.001 compared to wild-type mice. p < 0.05, p < 0.01 compared to vehicle-treated
animals (two-way ANOVA and Tukey’s post hoc test).
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Table 1
Statistical analysis of the ACEA effects in the pre-symptomatic phase at the cognitive level in APP/PS1 mice
Pre-symptomatic phase
Memory Learning (Active avoidance)
Recognition index Conditioned changes Day1 Day2 Day3 Day4 Day5 AUC
Three-way ANOVA
Factors
Day (repeated) N.A. F(4,115) = 20.68, N.A.
p <0.001 N.A.
Genotype N.A. F(1,115) = 44.70, N.A.
p <0.001
Treatment N.A. N.S. N.A.
Interaction
Day × genotype N.A. N.S. N.A.
Day × treatment N.A. N.S. N.A.
Genotype × treatment N.A. F(1,115) = 15.51, N.A.
p <0.001
Day × genotype × treatment N.A. N.S. N.A.
Two-wayANOVA
Factors
Genotype F(1,29) = 16.06, F(1,23) = 8.44, F(1,23) = 9.82, F(1,23) = 8.99, F(1,23) = 12.23, F(1,23) = 11.76, F(1,23) = 12.28,
p <0.001 p <0.01 p <0.01 p <0.01 p <0.01 p <0.01 p <0.01
Treatment N.S. N.S. N.S. N.S. N.S. N.S.
Interaction F(1,29) = 11.80, N.S. N.S. N.S. F(1,23) = 6.51, F(1,23) = 5.32, F(1,23) = 4.56,
p <0.01 N.S. N.S. N.S. p <0.05 p <0.05 p <0.05
Tukey’s post hoc test
WT Veh vs APP/PS1 Veh p <0.001 p <0.05 p <0.05 p <0.05 p <0.001 p <0.01 p <0.01
WT Veh vs WT ACEA N.S. N.A. N.A. N.A. N.A. N.A. N.A.
APP/PS1 Veh vs APP/PS1 ACEA p <0.05 N.A. N.A. N.A. N.S. N.S. p <0.05
WT ACEA vs APP/PS1 ACEA N.S. N.S. N.S. N.S. N.S. N.S. N.S.
Three-way ANOVA with day (repeated measures), genotype and treatment as between-subjects factors was applied for learning analysis. A sinteraction between genotype and treatment was
significant, subsequent two-way ANOVA with genotype and treatment as between-subjects factors was performed. For memory studies, two-way ANOVA with genotype and treatment as between-
subjects factors was applied. When one factor or interaction between factors were significant, comparisons between groups were performed by Tukey’s post hoc test. N.A., not applicable. N.S., not
significant difference. See Materials and methods for details.
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Table 2
Statistical analysis of the ACEA effects in the early symptomatic phase at the cognitive level in APP/PS1 mice
Symptomatic phase
Memory Learning (Active avoidance)
Recognition index Conditioned changes AUC
Day1 Day2 Day3 Day4 Day5
Three-way ANOVA
Factors
Day (repeated) N.A. F(4,127) = 16.40, N.A.
p <0.001
Genotype N.A. F(1,127) = 60.88, N.A.
p < 0.001
Treatment N.A. N.S. N.A.
Interaction
Day × genotype N.A. N.S. N.A.
Day × treatment N.A. N.S. N.A.
Genotype × treatment N.A. F(1,127) = 4.59, N.A.
p < 0.05
Day × genotype × treatment N.A. N.S. N.A.
Two-way ANOVA
Factors
Genotype F(1,27) = 20.13, N.S. F(1,23) = 13.04, F(1,25) = 18.19, F(1,25) = 25.90, F(1,25) = 27.24, F(1,25) = 25.53,
p < 0.001 N.S. p < 0.001 p < 0.001 p < 0.001 p < 0.001 p < 0.001
Treatment F(1,27) = 10.33, p < 0.01 N.S. N.S. N.S. N.S. N.S. N.S.
Interaction F(1,27) = 7.05, p < 0.05 N.S. N.S. N.S. N.S. N.S. N.S.
Tukey’s post hoc test
WT Veh vs APP/PS1 Veh p < 0.001 N.A. p < 0.01 p < 0.05 p < 0.05 p < 0.05 p < 0.01
WT Veh vs WT ACEA N.S. N.A. N.A. N.A. N.A. N.A. N.A.
APP/PS1 Veh vs APP/PS1 ACEA p < 0.01 N.A. N.A. N.A. N.A. N.A. N.A.
WT ACEA vs APP/PS1 ACEA N.S. N.A. N.S. N.S. N.S. N.S. p < 0.05
Three-way ANOVA with day (repeated measures), genotype and treatment as between-subjects factors was applied for learning analysis. As interaction between genotype and treatment was
significant, subsequent two-way ANOVA with genotype and treatment as between-subjects factors was performed. For memory studies, two-way ANOVA with genotype and treatment as between-
subjects factors was applied. When one factor or interaction between factors were significant, comparisons between groups were performed byTukey’s post hoc test. N.A., not applicable. N.S., not
significant difference. See Materials and methods for details.
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Fig. 4. A) Schematic representation of the 9 cortical areas (dashed squares) and the hippocampal section (dotted ellipse) evaluated for A
burden in each animal (B). Representative images of the A immunoreactivity in cortical sections of APP/PS1 mice treated during the pre-
symptomatic phase (upper panels) or during the early symptomatic phase (lower panels). Scale bar represents 100m. C) Cortical A burden
in APP/PS1 mice was not modified by the chronic ACEA treatment during the pre-symptomatic phase or during the early symptomatic phase.
D) Compared to cortex, the A burden in hippocampus of APP/PS1 mice was relatively low. ACEA did not modify the hippocampal A
burden during the pre-symptomatic phase or during the early symptomatic phase. Counts are expressed as the mean values ± SEM (n = 7–9 per
group).
pre-symptomatic (t(8) = 3.43, p < 0.01) or symptomatic
phase (t(8) = 3.24, p < 0.05) (Fig. 7A, B, and E). In con-
trast, ACEA did not significantly modify the microglial
activation in the area surrounding the Aplaques at any
phase (Fig. 7C, D, and F).
The effect of ACEA was not dependent upon
direct CB1 stimulation on astrocytes since CB1 was
not expressed in astrocytes in the neocortex of
APP/PS1 mice, as evidenced by the lack of colo-
calization between CB1 and GFAP immunostaining
(Fig. 8A). However, a reduction in the expression of
the pro-inflammatory IFN- protein was observed in
the ACEA-treated APP/PS1 astrocytes (t(8) = 2.12,
p < 0.05), suggesting a possible mechanism explaining
the effect of ACEA in those animals (Fig. 8B-F). IFN-
expression was absent in microglia (data not shown).
ACEA reduced the GSK3β phosphorylation at
Ser9 induced by Aβ in vitro and in vivo
A has been reported to induce GSK3 phospho-
rylation at Tyr216 as a harmful mechanism which
involved the downstream phosphorylation of-catenin
[25]. Interestingly, antioxidants protect against A
neurotoxicity, increasing GSK3 phosphorylation at
Ser9 [25] and avoiding -catenin inactivation. Since
cannabinoids have been previously reported to induce
GSK3 phosphorylation at Ser9 [26], we addressed
the relationship of GSK3 with neuroprotection
against A challenge. ACEA treatment prevented
the decrease in phospho-Ser9-GSK3 levels induced
by A in cortical neurons, as revealed by double-
immunofluorescence and western blotting techniques
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Fig. 5. A) Soluble A40 and A42 concentrations or (B) the ratio between the two soluble A forms were not modified in cortical homogenates
from APP/PS1 mice chronically treated with ACEA during the pre-symptomatic phase (left) or during the early symptomatic phase (right)
when compared to corresponding vehicle-treated controls. Data are expressed as the mean values ± SEM (n = 3–6 per group). C) Turbidometric
analysis of A42 aggregation in the presence of 0.1 and 1M ACEA. This CB1 agonist was not able to modify the A aggregation kinetics in
vitro. Data are the mean ± SEM of 3 independent experiments.
(Fig. 9), correlating with the observed neuroprotec-
tion (Fig. 1). This ACEA effect was significantly
avoided when a specific antagonist of CB1 recep-
tors was used (rimonabant; Fig. 9B and C). For
western blotting analysis, one way-ANOVA indi-
cated a treatment effect (F(3,12) = 11.90, p < 0.001).
Subsequent Tukey’s post hoc test revealed a significant
reduction of phospho-Ser9-GSK3 levels in neurons
challenged with A (p < 0.05), which was reduced
by ACEA (p < 0.01). Rimonabant blocked the ACEA-
induced effect (p < 0.01). Moreover, APP/PS1 mice
acutely treated with ACEA exhibited higher p-
Ser9-GSK3 levels in cortical homogenates when
compared to vehicle-treated animals, as revealed by
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Fig. 6. Representative images of the CB1 (red, A, D, G, and J) and A (green, B, E, H, and K) double-immunofluorescence in coronal sections
of wild-type (Vehicle: A to C; ACEA: G to I) and APP/PS1 mice (Vehicle: D to F; ACEA: J to L). C, F, I, and L) merge. Nuclei are stained
in blue. Scale bar represents 75m. M) Densitometric quantification of CB1 labeling revealed no CB1 downregulation in the free A cortical
areas (white-line squares, A, D, G, and J) in chronically ACEA-treated animals. Data are expressed as the mean values ± SEM (n = 5 pictures
from each animal, 3 animals per group) p < 0.05 compared to wild-type mice (two-way ANOVA and Tukey’s post hoc test).
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Fig. 7. Double immunofluorescent staining of glial cells (red) and A plaques (green). A to B) Astroglial response in the surrounding A
plaque area. Antibody against GFAP was used to specifically stain astrocytes. ACEA induced a reduction in the astroglial reactivity (B). C to
D) Microglial response in the surrounding A plaque area. Antibody against Iba1 was used to specifically stain microglia. Scale bar represent
100m. E) Quantification of the GFAP density with respect to A plaque areas indicated a significant reduction in the astroglial response after
chronic treatment with ACEA at both pre-symptomatic and symptomatic stages. However, no difference was observed in the microglial response
in ACEA-treated animals (F). Data are expressed as the mean values ± SEM (n = 5 pictures from each animal, 5 animals per group). p < 0.05,
p < 0.01 compared to vehicle-treated mice (Student’s t test analysis).
two-way ANOVA (Genotype, F(1,16) = 5.79, p < 0.05;
Treatment, (F(1,16) = 10.61, p < 0.01) and Tukey’s post
hoc test (p < 0.05) (Fig. 9D and E).
Reduced tau phosphorylation at Thr181 in the
area surrounding Aβ deposition in ACEA-treated
AβPP/PS1 mice
Considering the evidence demonstrating that the
neuronal microtubule-associated protein tau is highly
phosphorylated by GSK3, including the Thr181 site
[27, 28], and the relevance of tau in AD, we aimed
to examine whether ACEA could diminish tau phos-
phorylation. Double immunofluorescence techniques
revealed that only small amounts of phospho-tau could
be seen in the area surrounding mature plaques in
APP/PS1 mice during the early symptomatic phase.
However, ACEA was able to reduce the expression
of tau phosphorylated at Thr181 in the vicinity of
A plaques in APP/PS1 mice (t(8) = 2.57, p < 0.05)
(Fig. 10).
DISCUSSION
Here we provide behavioral and molecular findings
supporting the preventive and therapeutic properties
of the CB1 cannabinoid receptor agonist ACEA in a
familial AD transgenic mouse model when adminis-
tered at pre-symptomatic or early symptomatic stages
of the disease.
In a preliminary study, we observed that the CB1
receptor agonist ACEA conferred neuroprotection
against the cytotoxic effect of A42 oligomers to cor-
tical neurons in culture. This result was in agreement
with a previous study revealing that the elevation of
the endogenous cannabinoid 2-AG, a full agonist for
cannabinoid receptors, was also capable of preventing
and suppressing A-induced neurodegeneration and
apoptosis of hippocampal neurons in culture [19]. Con-
sidering these observations, we aimed to test whether
ACEA could also present beneficial properties in an in
vivo model of AD.
As a first step, we evaluated the availability and
distribution of the CB1 receptor in double transgenic
APP/PS1 mice at different stages of the neurodegen-
erative process, since alterations in the levels of the
ACEA target could compromise the effectiveness of
the cannabinoid compound. Previous studies based on
human postmortem brain samples suggested that the
CB1 receptor could be involved in the pathophysiol-
ogy of the disease. The analysis of AD brains revealed
reduced CB1 expression in neurons farther from the
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Fig. 8. A) Double immunofluorescent staining of CB1 (red) and GFAP (green) showed no CB1 receptor expression in astrocytes in the neocortex
of APP/PS1 mice. Nuclei are stained in blue. Scale bar represents 75m. B to E) The pro-inflammatory cytokine IFN- (green) is specifically
expressed in the astrocytes (GFAP, red). Inset, higher magnification of the astrocytes indicated by white arrows. F) Quantification of the IFN-
density with respect to GFAP area revealed a reduction in the expression of this pro-inflammatory cytokine in APP/PS1 mice chronically
treated with ACEA when compared to vehicle-treated mutants. Scale bar represents 50m. Data are expressed as the mean values ± SEM (n = 5
pictures from each animal, 5 animals per group). p < 0.05 compared to vehicle-treated mice (Student’s t test analysis).
plaque [13, 29]. However, some others reported no
changes in CB1 receptor levels in AD brains [30, 31]. In
agreement with the first studies, APP/PS1 mice pre-
sented a substantial reduction of CB1 receptor levels
from 6 months of age in the cortical areas not associated
with A deposition as well as in the area surrounding
A plaques, which was age-dependently aggravated.
Similar CB1 reductions were recently reported in the
hippocampus of the same animal model of AD [32].
Moreover, APP/PS1 mice presented higher levels
of CB1 receptor in the cortex than wild-type mice
at 3 months of age, suggesting a possible mecha-
nism attempting to reduce the latent neurodegenerative
process in mutant mice. These results point out on
one hand that CB1 receptor signaling efficacy could
be compromised in advanced pathological stages,
exacerbating the ongoing neurodegeneration, as has
been also suggested for the normal age-related decline
of cognitive functions [33]. On the other hand, these
findings suggest the importance of evaluating the effect
of the CB1 receptor agonist at early stages of the
neurodegenerative process, when the levels of CB1
receptor are still preserved.
Some earlier reports indicated that the admin-
istration of natural and synthetic cannabinoids or
endocannabinoid reuptake blockers in rodents reduced
the pro-inflammatory responses and memory impair-
ment associated with the intracerebral inoculation
of A peptide [13, 15, 34]. In contrast, some oth-
ers did not succeed in revealing beneficial effects
of a potent synthetic cannabinoid in an AD model
[35]. Interestingly, our study reveals for the first time
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Fig. 9. ACEA increased the GSK3 phosphorylation (Ser9) in cortical primary cultures when challenged with A42 oligomers and
in the cerebral cortex of APP/PS1 mice. A) Double immunofluorescent staining of phospho-GSK3 (green) and tubulin (red)
in cortical primary culture challenged with 1M A42 oligomers and treated with 1M ACEA. B) Representative western blot
revealing the CB1-dependent ACEA reversion of the A-induced dephosphorylation of GSK3 in neuronal cultures and the inhi-
bition of ACEA effect when the CB1 blocker rimonabant is present. C) Data are the mean ± SEM of 6 independent experiments
performed by western blot. p < 0.05; p < 0.005 (one-way ANOVA followed by Tukey’s post hoc analysis). D) Representative west-
ern blot showing the increase in the GSK3 phosphorylation (Ser9) in cortical homogenates after acute administration of ACEA
(1.5 mg/kg) in APP/PS1 mice. E) Data are the mean ± SEM of 5 mice per group. p < 0.05 (two-way ANOVA and Tukey’s post hoc
test).
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Fig. 10. Only small amounts of phospho-tau were seen in the area surrounding mature plaques in APP/PS1 mice at 8 months of age (A).
However, ACEA was able to reduce the expression of tau phosphorylated at Thr181 (red) in the area surrounding A plaques (green) in
APP/PS1 mice (B). C) Densitometric quantification of the phospho-tau Thr181 respect to A plaque areas. Data are expressed as the mean
values ± SEM (n = 5 pictures from each animal, 5 animals per group) p < 0.05 compared to vehicle-treated APP/PS1 animals (Student’s
t test analysis).
positive behavioral effects of a selective CB1 recep-
tor agonist in a transgenic animal model of the disease
that mimics the progressive cognitive deficiency and
the A deposition occurring in familial AD brains
[21]. Thus, chronic treatment with a non-amnesic dose
of the CB1 receptor agonist ACEA during the pre-
symptomatic phase of the pathology prevented the
cognitive impairment exhibited by APP/PS1 mice
at 6 months of age. Furthermore, chronic admin-
istration of ACEA to APP/PS1 animals aged 6
months at the beginning of the experiment partially
reversed their cognitive deficits, improving memory
but not the performance of a more complex learn-
ing task, such as the active avoidance paradigm, at
the end of the treatment. These data suggest that
the efficacy of the cannabinoid compounds could be
inversely proportional to the disease progression stage
at the beginning of the treatment. Importantly, chronic
treatment with ACEA did not induce a CB1 down-
regulation in the neocortex of APP/PS1 mice, as
was previously observed after prolonged exposure to
different cannabinoid compounds [36, 37], suggest-
ing that the low ACEA dose employed in the present
study did not induce a tolerance to the CB1 stimulation
effects.
The activation of CB1 receptor has been widely
reported to impair learning and memory. High doses
of CB1 agonists impair memory formation and pro-
duce deficits in working and short-term memory by
regulating neurotransmission and selectively affecting
encoding processes [24, 38]. However, it is impor-
tant to highlight that our data were obtained in a
different scenario, for different reasons. First, we
administered a non-amnesic dose of CB1 agonist,
which did not produce memory impairment after
acute administration (data not shown). Second, we
administered the cannabinoid compounds to animals
continuously exposed to A insult. The endogenous
cannabinoid system is known to trigger different mech-
anisms devoted to maintaining cellular homeostasis
and protecting neurons against the deleterious con-
sequences of toxic molecules. Thus, CB1 receptor
promotes protection against excitotoxicity [8, 9] and
against other insults related to neurodegenerative pro-
cesses [39–41]. Considering these previous reports and
our present observations about the reduction of the
A-induced neurotoxicity in the ACEA-treated cor-
tical neuron culture, the beneficial cognitive effects
observed after the chronic ACEA treatment could
be directly related with the neuroprotection against
the A insult conferred by the stimulation of CB1
receptors. This neuroprotective effect is supported by
the demonstrated capacity of ACEA to reverse the
A-induced dephosphorylation of GSK3 in neu-
ronal cultures. Similarly, the acute administration of
ACEA increased the GSK3 Ser9 phosphorylation
in mice. Our results are in line with previous stud-
ies demonstrating that the stimulation of CB1 receptor
activates the pro-survival PI3K/Akt pathway, leading
to the inactivation of GSK3 by phosphorylation at
Ser9 [26]. GSK3 is known to play an important
role in mediating neuronal fate and synaptic plastic-
ity [42]. In AD, GSK3 is considered as a possible
link between Apeptide and the neuronal microtubule-
associated tau protein [27], since A promotes GSK3
over-activation, which in turn accounts for tau hyper-
phosphorylation and which subsequently reduces the
ability of tau to promote microtubule assembly
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[27, 28]. Moreover, GSK3 over-activity has also been
related to other hallmarks of AD such as memory
impairment and the inflammatory responses medi-
ated by microglia [43–45]. Taking into account this
evidence, we evaluated whether the ACEA-induced
reduction in GSK3 activity correlated with alter-
ations in tau phosphorylation in mice. Effectively,
the levels of tau phosphorylated at the Thr181 site,
which is a target of the GSK3 kinase activity [28],
were decreased in the area surrounding A plaques
in ACEA-treated APP/PS1 mice. This result is in
agreement with a previous study demonstrating that
CB1 receptor selective activation reduced tau pro-
tein hyperphosphorylation in co-cultured neurons [46].
Thus, our results suggest that the ability of ACEA to
diminish the deleterious impact of GSK3 could be a
possible mechanism explaining the positive effect of
this CB1 receptor agonist in APP/PS1 mice. How-
ever, the reduction in tau phosphorylation by itself
deserves to be considered with caution, since our ani-
mal model of AD presents only small amounts of
phospho-tau in dystrophic neurites, which are never
on a par with those seen in AD brains, and which
do not produce neurofibrillary tangles at any age in
APP/PS1 mice [22]. Thus, the contribution of the
abnormal tau phosphorylation to the neurodegenera-
tive process occurring in APP/PS1 mice is assumed
to be minor.
In addition, the cognitive improvement was asso-
ciated with the reduction of the astroglial reactivity
in the vicinity of A plaques after chronic ACEA
treatment. This finding is in agreement with a pre-
vious report revealing that ACEA was able to blunt
A-induced reactive astrogliosis in vitro and in A-
inoculated rats [15]. However, this observation cannot
be explained by a direct effect of ACEA through
astrocytic CB1 stimulation since we were not able
to reveal CB1 expression in reactive astrocytes in the
neocortex of APP/PS1. The presence and functional
significance of CB1 receptors in astrocytes is contro-
versial [5]. While several studies have shown their
presence in cultured astrocytes and associated their
activity to the reduction of inflammatory mediators
[47–51], few studies reported astrocytic CB1 expres-
sion in specific brain areas and suggested a role
of CB1 receptor in neuron-astrocyte communication
[52–55]. In line with the studies relating CB1 recep-
tors to the regulation of inflammatory mediators, our
results revealed an ACEA-induced reduction in the
expression of the pro-inflammatory cytokine IFN-
in astrocytes. Interferons represent crucial modula-
tors of the central and peripheral immune responses
and previous studies demonstrated the capability of
the endocannabinoid system to modulate interferon
levels [56], supporting the idea that the reduction in
the inflammatory processes mediated by interferons
could be a mechanism accounting for the CB1 agonist’s
positive effect in APP/PS1 mice. However, further
studies are needed in order to address the implica-
tion of such observations in the cognitive improvement
reported in ACEA-treated APP/PS1 mice, as well
as to increase knowledge of the mechanisms underly-
ing the reduced astroglial reactivity observed in those
animals.
Regarding the microglial response to A deposi-
tion, ACEA was not able to modify the microglia
activation. The apparent controversy with respect
to previous studies indicating cannabinoid-induced
reductions in microglial responses to A [13, 16]
could be explained by the fact that such reports were
based on mixed CB1/CB2 agonists or on microglial
cell lines. CB1 receptor is known to be expressed
in microglial cells barely under culture conditions
[5], so the lack of effect of a specific CB1 agonist
observed in the microglia of our brain samples is
not unexpected. On the other hand, these observa-
tions suggest that the use of a non-selective agonist
for CB1/CB2 receptors could probably provide a
combined effect of the CB1-mediated reduction in
neurotoxicity and astroglial response to A, with CB2-
mediated reduction of microglial toxicity, resulting in
a higher benefit.
Our present findings indicate that CB1 receptors do
not participate significantly in the production, aggre-
gation, or clearance of the A in APP/PS1 mice.
Thus, ACEA did not change A production attending
to both A40 and the more fibrillogenic A42 solu-
ble forms in mouse brain. Moreover, ACEA did not
produce any effect on A aggregation in vitro, which
correlated with a lack of difference in the A bur-
den on treated animals. Similar results were previously
reported for another synthetic cannabinoid in another
animal model of AD [35]. Hence, considering that
ACEA did not alter A processing, we may conclude
that the protection conferred on neurons challenged
with A by decreasing GSK3 activity, the reduction
of astroglial reactivity and the decreased production
of pro-inflammatory proteins such as IFN- could be
the major effects mediating ACEA-induced cognitive
improvement in APP/PS1 mice.
In summary, our present results reinforce the
hypothesis that targeting the endocannabinoid system
could offer a versatile approach for the development
of novel therapeutic strategies against AD.
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